Boehringer Ingelheim and OSE Immunotherapeutics announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumours.
Alexion Pharmaceuticals announced the presentation of new data demonstrating that ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, provided consistent efficacy and safety through 52 weeks in the extension of the Phase 3 study of ULTOMIRIS and SOLIRIS (eculizumab) in complement inhibitor-naïve, adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has achieved statistically significant and clinically meaningful improvement in treating hyperkalaemia in patients with end-stage renal disease (ESRD) on haemodialysis in phase 111b Dialize trial.
Janssen Pharmaceutical’s TREMFYA (guselkumab) succeeded in the phase 3 Discover programme by meeting the primary endpoints of American College of Rheumatology 20% improvement (ACR20) at week 24 in adult patients with active moderate to severe psoriatic arthritis (PsA).
Corvidia Therapeutics, a clinical stage biotechnology company, announced the initiation of patient screening for a Phase 2b dose-finding study of ziltivekimab.
Pfizer has announced positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).
Novartis announced that its Cosentyx (secukinumab) has achieved its primary and key secondary endpoint in the Maximise study of psoriatic arthritis (PsA).
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
ProtoKinetix, announced reaching the midpoint of a Phase-1 first-in-human clinical trial of AAGP PKX-001 treated islet cells used in conjunction with the Edmonton Protocol for the treatment of Type-1 diabetes.
AstraZeneca’s blood cancer drug Calquence (acalabrutinib) in combination with obinutuzumab met the primary endpoint at interim analysis in the phase 3 ELEVATE-TN trial in previously-untreated chronic lymphocytic leukaemia (CLL).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.